The field of molecular biology continues to evolve, driving demand for increasingly specialised oligonucleotide solutions across research, diagnostics, and therapeutic development. To support these growing requirements, metabion has expanded its DNA portfolio with new product categories, additional modification options, and the return of two widely used fluorescent technologies.
These latest additions provide researchers, clinical laboratories, and diagnostic providers with greater flexibility when designing oligonucleotides for a wide range of applications, from routine PCR assays to advanced therapeutic research.
New Product Categories
As part of the portfolio expansion, metabion has introduced two new product categories designed to address emerging scientific requirements.
DNA Longmers
DNA Longmers provide researchers with access to longer DNA oligonucleotides through a dedicated product category. These longer sequences support specialised applications in molecular biology, synthetic biology, assay development, diagnostics, and custom research workflows where standard oligonucleotide lengths may not be sufficient.
Standard Therapeutic Modifications
To support the growing field of therapeutic oligonucleotides, metabion has introduced a curated range of Standard Therapeutic Modifications. This category simplifies access to commonly used therapeutic modifications, enabling researchers to design oligonucleotides suitable for drug discovery, therapeutic development, and advanced molecular research.
New Modification Capabilities
In addition to the new product categories, metabion has expanded its modification portfolio with three new additions that offer researchers greater choice and flexibility.
MEX
MEX is a high-performance, licence-free alternative to HEX. Designed for fluorescence-based applications, MEX provides a practical solution for laboratories seeking reliable fluorescent labelling without licensing restrictions.
Atto 700
Atto 700 is a far-red fluorescent dye suitable for applications including qPCR multiplexing and fluorescence microscopy. Its spectral properties make it particularly useful for assays requiring multiple fluorescent targets while maintaining clear signal separation.
2′-MOE
2′-MOE (2′-O-Methoxyethyl) is a widely used modification in therapeutic oligonucleotides. This modification plays an important role in therapeutic research and development and is commonly incorporated into advanced oligonucleotide designs.
The Return of Two Popular Modifications
Responding to customer demand, metabion has also reintroduced two established modifications that remain highly relevant for modern assay development and molecular diagnostics.
BHQ-3®
BHQ-3® is a non-fluorescent quencher designed for qPCR applications and is particularly effective when paired with fluorophores operating in the far-red region of the spectrum. Its ability to reduce background fluorescence makes it a valuable component in probe design.
IRDye® 700
IRDye® 700 is a near-infrared fluorescent dye that enables highly sensitive detection while maintaining low background signal levels. Its performance characteristics make it suitable for a variety of fluorescence-based analytical applications.
Supporting Modern Research and Diagnostics
Together, these additions represent a significant expansion of metabion’s DNA portfolio. Researchers now have access to longer oligonucleotide sequences, therapeutic-focused modifications, new fluorescent dyes, and the return of trusted probe components that support assay sensitivity and performance.
Whether developing diagnostic assays, conducting molecular biology research, designing multiplex qPCR experiments, or advancing therapeutic oligonucleotide programmes, laboratories can benefit from a broader selection of high-quality oligonucleotide solutions tailored to modern scientific challenges.
With these portfolio enhancements, metabion continues its commitment to providing innovative, reliable, and flexible oligonucleotide products that help researchers achieve their scientific objectives with confidence.